Tumor necrosis factor blockade: Mechanism of action

被引:30
作者
Gottlieb, Alice B. [1 ]
机构
[1] Tufts Univ, New England Med Ctr, Dept Dermatol, Boston, MA 02111 USA
关键词
D O I
10.1038/sj.jidsymp.5650029
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Modulation of the immune response with tumor necrosis factor (TNF) blockers is not a new treatment strategy for many inflammatory disorders; however, relatively little is known about their specific mechanism of action. Understanding the mode of action, pharmacology, and pharmacokinetics of the monoclonal TNF antibodies, infliximab and adalimumab, and the soluble TNF receptor, etanercept, may therefore enable us to account for their differing clinical profiles. The aim of this supplement is to explore the roles and mechanisms of TNF and TNF blockade using in vitro pharmacological and in vivo animal modeling experiments, and in vivo studies of the effects of etanercept on the inflammatory cascade in patients with psoriasis.
引用
收藏
页码:1 / 4
页数:4
相关论文
共 44 条
[1]  
Akkoc N, 2006, ANN RHEUM DIS, V65, P499
[2]  
Akobeng Anthony K, 2006, J Pediatr Gastroenterol Nutr, V42, P589, DOI 10.1097/01.mpg.0000221896.45910.9a
[3]   Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial [J].
Antoni, C ;
Krueger, GG ;
de Vlam, K ;
Birbara, C ;
Beutler, A ;
Guzzo, C ;
Zhou, B ;
Dooley, LT ;
Kavanaugh, A .
ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 (08) :1150-1157
[4]   Infectious complications of tumor necrosis factor-α antagonists [J].
Bakleh, M ;
Tleyjeh, I ;
Matteson, EL ;
Osmon, DR ;
Berbari, EF .
INTERNATIONAL JOURNAL OF DERMATOLOGY, 2005, 44 (06) :443-448
[5]   Infliximab (REMICADE) therapy in the treatment of pediatric Crohn's disease [J].
Baldassano, R ;
Braegger, CP ;
Escher, JC ;
DeWoody, K ;
Hendricks, DF ;
Keenan, GF ;
Winter, HS .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2003, 98 (04) :833-838
[6]   Treatment of active ankylosing spondylitis with infliximab:: a randomised controlled multicentre trial [J].
Braun, J ;
Brandt, J ;
Listing, J ;
Zink, A ;
Alten, R ;
Golder, W ;
Gromica-Ihle, E ;
Kellner, H ;
Krause, A ;
Schneider, M ;
Sörensen, H ;
Zeidler, H ;
Thriene, W ;
Sieper, J .
LANCET, 2002, 359 (9313) :1187-1193
[7]   Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial [J].
Chaudhari, U ;
Romano, P ;
Mulcahy, LD ;
Dooley, LT ;
Baker, DG ;
Gottlieb, AB .
LANCET, 2001, 357 (9271) :1842-1847
[8]  
Ehlers S, 2005, J RHEUMATOL, V32, P35
[9]   TUMOR-NECROSIS-FACTOR-ALPHA IS REQUIRED IN THE PROTECTIVE IMMUNE-RESPONSE AGAINST MYCOBACTERIUM-TUBERCULOSIS IN MICE [J].
FLYNN, JL ;
GOLDSTEIN, MM ;
CHAN, J ;
TRIEBOLD, KJ ;
PFEFFER, K ;
LOWENSTEIN, CJ ;
SCHREIBER, R ;
MAK, TW ;
BLOOM, BR .
IMMUNITY, 1995, 2 (06) :561-572
[10]  
*GEAR RHEUM ARTHR, 2006, ANN RHEUM DIS S, V65, pS498